After buoyant 3rd qtr, Valeant disappoints with weak full year result

28 February 2018

After a strong third quarter in which Valeant Pharmaceuticals (TSX: VRX) chipped away at its worryingly large debt mountain and posted strong profits courtesy of a one-off tax benefit, the Canadian drugmaker has disappointed investors with a less encouraging full year report.

The firm posted revenues just shy of analysts’ expectations at $8.7 billion, with net income of $2.4 billion, following generally accepted accounting principles (GAAP). In 2016, the firm reported revenues almost a billion dollars higher.

GAAP-earnings per share for the full year of 2017 was $6.83, as compared to -$6.94 for the full year of 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK